TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
CompletedPhase 1

Virtual Reality Cognitive Therapy for Alzheimer's Disease

To evaluate the usability, feasibility, and acceptability of VRCT iteratively on 36 AD/ADRD individuals with mild to moderate CI.

Saint Paul, Minnesota, United StatesView details
CompletedN/A

Transcranial Electromagnetic Treatment Against Alzheimer's Disease

This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to partici

Tampa, Florida, United StatesView details
Completed

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indicati

Boston, Massachusetts, United StatesView details
CompletedPhase 3

Multicenter Vitamin E Trial in Aging Persons With Down Syndrome

The purpose of this study is to determine the safety and effectiveness of 2,000 international units of Vitamin E (alpha tocopherol)on cognitive function of aging persons with Down syndrome. It is a randomized, double-blind, placebo-controll

Multiple locationsView details
TerminatedPhase 3

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated

Phoenix, Arizona, United States+81 moreView details
Completed

Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease

This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive im

Dallas, Texas, United StatesView details
CompletedPhase 3

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.

Phoenix, Arizona, United States+100 moreView details
UnknownPhase 4

The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)

To evaluate the relationship between Risperidone Treatment, Treatment Discontinuation Rate, and Quality of Life of patients with Alzheimer's Disease and BPSD.

Tainan, TaiwanView details
Unknown

Comparison of Dual Assignment, Cadence, and Gait Speed in Alzheimer's Dementia and Healthy Geriatric Individuals

Tests will be performed in individuals with Alzheimer's dementia to compare dual-task and gait with healthy geriatric individuals.

Multiple locationsView details
UnknownPhase 2

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

Physical exercise has proven to improve memory including in the elderly. Drugs developed to stop the underlying disease processes that cause Alzheimer's disease may succeed only with multimodal efforts to stimulate brain function.

West Los Angeles, California, United StatesView details
CompletedN/A

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood p

Seattle, Washington, United StatesView details
Completed

Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment

Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly.

Multiple locationsView details
TerminatedPhase 2

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat patients with m

Achim, Germany+11 moreView details
CompletedN/A

Effect of Blueberry Supplementation on Alzheimer's Biomarkers

The purpose of this study is to study the effects of blueberries on neuronal, glial, and pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for future confirmatory studies. The blood biomarkers to be m

Durham, North Carolina, United StatesView details
Completed

Verification Study and Reactivity Study for the Validity of QuQu Scale

Examine the construct validity, the test-retest reliability, the concurrent validity with the standard dementia rating scales and the reactivity of a novel dementia rating scale "QuQu scale: QUick QUestion scale" final for the evaluation of

Kitagun, Kagawa-ken, JapanView details
TerminatedPhase 3

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

Phoenix, Arizona, United States+197 moreView details
CompletedPhase 1

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

This is a randomized, open-label, cross-over, pharmacokinetic and pharmacodynamic PK/PD study. (Part A)The PK portion of the study is designed to evaluate the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a

Miami Lakes, Florida, United StatesView details
RecruitingPhase 1

BnH-015B Clinical Trial in Moderate Alzheimer's Disease

BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the BDNF/TRKβ and

Seoul, Jongno-gu, South KoreaView details
RecruitingPhase 3

A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

This is a 24-week prospective, randomized, double-blind, placebo-controlled, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate AD patients

Rome, Italy, ItalyView details
Unknown

The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease

Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the d

Guangzhou, Guangdong, ChinaView details
Load more trials